Jonathan Silverstein, Director at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 207,800 shares at $270.13 ($57.0M) on 2015-03-24, disclosed to the SEC on 2015-03-25.
Open-market sale of $57.0M ICPT by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $270.70 | 40,598 | $11.0M | 19.3% |
| 2 | $271.70 | 7,764 | $2.1M | 3.7% |
| 3 | $272.79 | 8,638 | $2.4M | 4.1% |
| 4 | $273.89 | 11,869 | $3.3M | 5.7% |
| 5 | $274.86 | 3,579 | $984K | 1.7% |
| 6 | $275.95 | 37,666 |
| $10.4M |
| 18.2% |
| 7 | $276.96 | 8,195 | $2.3M | 4.0% |
| 8 | $278.00 | 14,152 | $3.9M | 6.9% |
| 9 | $279.00 | 3,668 | $1.0M | 1.8% |
| 10 | $280.00 | 9,465 | $2.7M | 4.6% |
| 11 | $281.01 | 6,306 | $1.8M | 3.1% |
| 12 | $282.00 | 3,500 | $987K | 1.7% |
| 13 | $283.29 | 1,548 | $439K | 0.8% |
| 14 | $283.44 | 52 | $15K | 0.0% |
| 15 | $286.04 | 1,400 | $400K | 0.7% |
| 16 | $288.60 | 1,000 | $289K | 0.5% |
| 17 | $268.13 | 6,764 | $1.8M | 3.2% |
| 18 | $269.10 | 1,539 | $414K | 0.7% |
| 19 | $270.13 | 9,574 | $2.6M | 4.5% |
| 20 | $271.15 | 6,063 | $1.6M | 2.9% |
| 21 | $272.13 | 3,050 | $830K | 1.5% |
| 22 | $273.19 | 2,700 | $738K | 1.3% |
| 23 | $275.00 | 12,066 | $3.3M | 5.8% |
| 24 | $275.56 | 3,844 | $1.1M | 1.9% |
| 25 | $270.23 | 2,800 | $757K | 1.3% |
| Total | $274.41 avg | 207,800 | $57.0M | 100% |
| Filing → |
| GKOS | SELL | 2018-03-06 | $26.8M | — | Filing → |
| TORC | BUY | 2018-01-30 | $8.0M | — | Filing → |
| GKOS | SELL | 2017-09-05 | $22.5M | — | Filing → |